NCT04542213View on ClinicalTrials.gov

Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
HyperglycemiaCovid19
Interventions
DRUG

Linagliptin tablet

Linagliptin 5mg once daily plus a basal-bolus insulin scheme

DRUG

Insulin

Basal-bolus insulin scheme

Trial Locations (1)

37660

Hospital Regional de Alta Especialidad del Bajìo, Leòn

All Listed Sponsors
lead

Hospital Regional de Alta Especialidad del Bajio

OTHER

NCT04542213 - Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19 | Biotech Hunter | Biotech Hunter